Clinical Studies

The primary focus of EuroVacc’s clinical program is on the development of its leading candidates DNA-C+NYVAC-C.

The initial studies (EV01 and EV02) were funded by the European Commission 5th Framework program. EV03/ANRSVAC20 was performed jointly with Agence nationale de recherches sur le sida et les Hépatites virales (ANRS). In collaboration with Division of AIDS of National Institute of Health and HIV Vaccine Trial Network, EuroVacc has also sponsored a study to evaluate the safety and immunogenicity of a prime-boost combination with NYVAC with Ad5 vector based vaccines (HVTN078).

Further to the prophylactic studies, through the collaboration with European Commission funded consortium “Evaluation of a New Therapeutic Vaccination Strategy for HIV infection (TheraVac)”, EuroVacc has also sponsored two therapeutic trials of NYVAC-B and MVA-B.
 

Preventative Trials

Protocol Nr. Description Sponsors Trials sites Status Publication
EV01 Phase I
Safety and Immunogenicity Study of NYVAC-C alone		 Imperial College London Switzerland & UK Completed Click here
EV02 Phase I
Safety and Immunogenicity comparing DNA-C prime and NYVAC-C boost versus NYVAC-C alone		 Eurovacc Switzerland & UK Completed Click here
EV03/ ANRSVAC20 Phase II
Immunogenicity and safety of 3 DNA-C prime followed by 1 NYVAC-C boost versus 2 DNA-C prime followed by 2 NYVAC-C boost		 EuroVacc & ANRS Switzerland, UK, Germany, France Completed Click here
RisVac02 A phase I study of MVA-B in healthy volunteers at low risk of HIV infection Hospital Cínic, Barcelona Spain Completed Click here
HVTN 078 A phase 1b clinical trial to evaluate the safety and immunogenicity of heterologous prime/boost vaccine regimens (NYVAC-B/rAd5 vs. rAd5/NYVAC-B) in healthy, HIV-1 uninfected, Ad5 seronegative adult participants EuroVacc& DAIDS, NIH Switzerland Ongoing

Therapeutic Trials

Protocol Nr. Description Sponsors Trials sites Status Publication
Theravac01 Phase I
safety of NYVAC-B in chronic HIV-1 infected patients successfully treated with HAART		 Eurovacc Switzerland Completed Click here
TheraVac02 Phase I
safety of MVA-B in chronic HIV-1 infected patients successfully treated with HAART		 Eurovacc The Netherlands Completed Click here